title: Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease.
abstract: It is recommended to investigate the serology of hepatitis B virus (HBV) and vaccinate seronegative patients at the time of diagnosis in inflammatory bowel diseases (IBD). This study aimed to investigate the efficacy of HBV vaccine and factors affecting the response.In this retrospective, observational study, HBV-seronegative IBD patients were administered 3 doses (at months 0, 1, and 6) recombinant 20  μg HbsAg. Patients' demographics, IBD attributes, and treatment methods were investigated as the factors with potential impacts on vaccination outcomes.One hundred twenty-five patients with IBD were evaluated. The number of patients with Anti-HBs >10  IU/L was 71 (56.8%), and the number of patients with anti-HBs >100  IU/L was 50 (40%). Age, disease activity, Crohn disease subtype, and immunosuppressive treatment (IST) were found to have significant effects on immune response (P = 0.011, P < 0.001, P = 0.003, and P < 0.001, respectively). With multivariate analysis, age < 45 years (OR 3.1, 95% CI 1.2-8.3, P = 0.020), vaccination during remission (OR 5.6, 95% CI 2.3-14, P < 0.001), and non-IST (OR 11.1, 95% CI 2.9-43.2, P = 0.001) had favorable effects on the occurrence of adequate vaccine response.The likelihood of achieving adequate immune response with standard HBV vaccination protocol in IBD is low. Selecting vaccination protocols with more potent immunogenicity is a better approach to achieve effective vaccine response in patients with multiple unfavorable factors.
authors.affiliation: From the Department of Gastroenterology, Katip Celebi University, Atatürk Training and Research Hospital (CC, FA, MA, ESY, SV, SG, EA, BÜ); Department of Gastroenterology, Şifa University, Faculty of Medicine (AK); Department of Internal Medicine (ZZG); and Department of Medical Microbiology, Katip Celebi University, Atatürk Training and Research Hospital, İzmir, Turkey (SGY).
authors.forename: Cem
authors.initials: C
authors.lastname: Cekic
authors.forename: Fatih
authors.initials: F
authors.lastname: Aslan
authors.forename: Adnan
authors.initials: A
authors.lastname: Kirci
authors.forename: Zeynep Zehra
authors.initials: ZZ
authors.lastname: Gümüs
authors.forename: Mahmut
authors.initials: M
authors.lastname: Arabul
authors.forename: Elif Sartas
authors.initials: ES
authors.lastname: Yüksel
authors.forename: Sezgin
authors.initials: S
authors.lastname: Vatansever
authors.forename: Süreyya Gül
authors.initials: SG
authors.lastname: Yurtsever
authors.forename: Emrah
authors.initials: E
authors.lastname: Alper
authors.forename: Belks
authors.initials: B
authors.lastname: Ünsal
mesh_terms: D000328:Adult; D000917:Antibody Formation / Q000502:physiology*; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines